Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience

Sylvester, John; Blasko, John C.; Grimm, Peter; Meier, R.; Malmgren, Judith A.

doi:10.1016/s0360-3016(03)00739-9

Cited by 155 publications

(67 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are among the best published in this category of locally advanced prostate cancers [11,25,36]. They also compare favourably with exclusive EBRT data published by Zelefsky et al [39,40].…”

Section: Discussionsupporting

confidence: 90%

“…Numerous papers have been reported on Bt as a boost to EBRT in the treatment of locally advanced prostatic cancer [11,25,36]. Most of the recent works presented the 5 y bned according to the ASTRO criteria and the different groups of intermediate or unfavourable prognosis based on three adverse criteria (PSAO10 ng/ml, Gleason scoreR7 and clinical stageRT2b).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Nickers¹,

Coppens

Leval

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

Background and purpose: To evaluate on 201 locally advanced prostatic cancers prospectively treated in a phase II trial, the efficacy of a combination of external beam radiotherapy (39.6 Gy) and 192 Ir low dose rate brachytherapy (Bt) (40-45 Gy).Patients and methods: Sixty-four patients were included in the intermediate prognosis group with only one of the following adverse factors (PSAO10 ng/ml, Gleason scoreR7 or clinical stageRT2b) and 137 in the unfavourable group when at least two of these factors were present.Results: The actuarial 4 years biochemical no evidence of disease is 82.8% for the entire population. It is, respectively, 97 and 76% in the intermediate and unfavourable prognosis groups (P!0.0001). GradeR3 late urinary complications occurred in 13 patients (6.5%). Eight patients (4%) presented late grade 2 rectal complications but no grades 3-5 was observed.Conclusions: Even if an a/b of 1.5-3 Gy theoretically favours the use of a high dose rate mode of irradiation, the early results presented here are as good as those reported for similar groups of patients with high dose rate treatments. Late toxicity is identical but our urinary toxicity is within the less favourable and rectal toxicity within the most favourable results.We can postulate that while inducing very high hyperdosage regions (V150) mainly focused on the peripheral zone, most of the Bt techniques consist of a more ablative treatment. Many of the radiobiological studies on Bt did not in fact take into account the heterogeneity of irradiation inside the CTV. This study highlights the need to explore pulsed dose rate therapies, permanent implant and new available radioisotopes such as 169 Ytterbium that will offer the safety of low and lower dose rates. The actual late toxicity of the different Bt techniques is not yet inexistent indeed. q

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Nickers¹,

Coppens

Leval

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…7,8 The overall Seattle published series of 634 patients, 402 treated with an implant alone (Iodine 125/Palladium-103), and 232 treated by an implant and external beam radiation revealed a progression-free survival rate of 77%. 8,9 No patients underwent lymph node sampling or androgen ablation, and biochemical relapse-free survival was determined by two successive PSA rises rather than the more standard ASTRO criteria of three. When stratified by risk factors, see Table 1.…”

Section: Long-term Resultsmentioning

confidence: 99%

“…However, if the seminal vesicles appear clear, combination therapy has been used with good effect, as demonstrated in a number of series with up to 50% biochemical-free survival at 10 y. 9,24 Brachytherapy may be the treatment of choice in those patients who suffer from colitis or have had previous radiotherapy for testicular tumours due to the small volume of normal tissue irradiated.…”

Section: Complicationsmentioning

confidence: 99%

Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer

Langley

Laing

2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

This article on permanent iodine-125 seed prostate brachytherapy reviews the techniques, results, and patient selection issues for early prostate cancer. The longterm 10 y results of brachytherapy from Seattle, and their reproducibility in other centres both in the USA and UK are reported. The use of hormone therapy in brachytherapy and the value of combining external beam radiotherapy with a brachytherapy implant are discussed. Reviewed comparative data show the similarity of biochemical survival in patients treated with brachytherapy, radical prostatectomy, and external beam radiotherapy. The role of brachytherapy as a first-line treatment option for patients with prostate cancer is demonstrated.

show abstract

“…In addition, studies comparing the entire standard treatment regimens (RP, BT, EBRT, ADT and NT) for the overall survival and disease specific survival using the SEER-Medicare data set are currently inadequate, BT or EBRT have not been compared with NT. BT, alone or in combination with EBRT, has become widely accepted as first-line treatments for patients with localized CaP, and relevant outcomes studies have been conducted in smaller, center-based group of patients, but not in population-based data (15)(16)(17). We aimed to investigate survival outcomes in the State of Ohio, using the CancerAging Linked Database (CALD), which mirrors the structure of the SEER-Medicare files, and combines data from the Ohio Cancer Incidence Surveillance System (OCISS) and Medicare enrollment and claims files.…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy and Survival in Prostate Cancer Patients: A Population-Based Study

Zhou

Ellis

Cherullo

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-To investigate the association of overall and disease specific survival with the 5 standard treatment modalities for prostate cancer (CaP): radical prostatectomy (RP), brachytherapy (BT), external beam radiation therapy (EBRT), androgen deprivation therapy (ADT), and no treatment (NT) within 6 months after CaP diagnosis.Methods and Materials-The study population included 10,179 men 65 years and older with incident CaP diagnosed between 1999 and 2001. Using the linked Ohio Cancer Incidence Surveillance System, Medicare, and death certificate files, we analyzed overall and disease specific survival through 2005 among the five clinically accepted therapies. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Results-Disease NIH Public Access Author ManuscriptInt J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2010 January 1. Conclusions-The present population-based study indicates that RP and BT are associated with improved survival outcomes. Further studies are warranted to improve clinical determinates in the selection of appropriate management of CaP, and to improve predictive modeling for which patient subsets may benefit most from definitive therapy, versus conservative management and/or observation.

show abstract

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience

Cited by 155 publications

References 21 publications

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer

Radiotherapy and Survival in Prostate Cancer Patients: A Population-Based Study

Contact Info

Product

Resources

About